Table 1.
Strain | Treatment | LC50 (95% CL) (mg·L−1) | Slope ± SE | x 2 | RR | SR |
---|---|---|---|---|---|---|
YYS | Chlorantraniliprole | 12.76 (11.08–14.76) | 2.72 ± 0.31 | 5.96 | 1.00 | 1.00 |
Chlorantraniliprole + 5-NU | 10.48 (8.95–12.27) | 2.42 ± 0.35 | 5.17 | - | 1.22 | |
Chlorantraniliprole + SUL | 11.27 (9.76–13.03) | 2.70 ± 0.32 | 7.72 | - | 1.13 | |
YYR | Chlorantraniliprole | 565.48 (510.42–626.47) | 3.67 ± 0.22 | 7.31 | 44.32 | 1.00 |
Chlorantraniliprole + 5-NU | 167.47 (146.78–191.08) | 2.97 ± 0.29 | 2.68 | - | 3.38 * | |
Chlorantraniliprole + SUL | 158.71 (139.32–180.79) | 3.08 ± 0.28 | 7.75 | - | 3.56 * |
* Indicates statistical significance. CL, Confidence limits; RR = LC50 of YYR strain/LC50 of YYS strain; SR = LC50 of chlorantraniliprole/LC50 of chlorantraniliprole + synergist.